September 2017 In a clinical trial, N-acetylcysteine did not help adults reduce their cannabis use, despite having been effective for adolescents in a previous trial. The results indicated that if adults are able to benefit from the medication, they will likely require a different treatment regimen than adolescents.
Several effective medications are now available for treating opioid use disorder but many patients who could benefit do not receive them. Some patients who receive the medications face challenges to staying in treatment.
In this international trial, participants who received the intervention engaged in HIV treatment, achieved viral suppression at higher rates, and died at half the rate of participants in a control group.
Interim treatment with buprenorphine significantly improved the psychiatric symptoms of people awaiting comprehensive treatment for opioid use disorder (OUD). Buprenorphine treatment, even without concurrent psychosocial counseling, may help patients with no, or delayed, access to comprehensive OUD treatment.
Mindful Awareness in Body-Oriented Therapy (MABT) improved emotion regulation, reduced craving, and promoted abstinence in women with a history of trauma and emotional problems receiving outpatient treatment for substance use disorder.